I'm sensing a lot of speculation on this post and I'm not 100% sure what you're insinuating with regards to James being "100% upfront"
agree with you on Bpharma however.
how do you know the higher IV cohorts we're simply to elicit in toxicity? hard to say if they were toxic if it was never proved during trials. there are a lot of market drugs with higher dosing levels that can be toxic too bare in mind. from what James explained to the market the 6000mg was meant to be within what RCE believes would be efficacious levels, hence why the rest of the trial was abandoned. it would be misleading for the company to say otherwise. I understand what you're trying to say that if we pushed dosing higher we would have likely found an unsafe level with "peak plaster levels" I don't know enough about the subject and from what I've read on your post RCE have dodged the question you posed to them via email ect. so from your research are you sure that peak plasma levels are required or are you just going off previous announcements and connecting the dots?
from the market update 6 months ago they were a fairly excited about the discovery that R327 is excreted from the body through the urinary tract. I think UTI will get a lot of air play for the next 12months
RCE Price at posting:
55.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)